New drug shows promise for Long-Term ulcerative colitis control

NCT ID NCT03648541

Completed Disease control Sponsor: Boehringer Ingelheim Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at the long-term safety of a drug called spesolimab in adults with moderate to severe ulcerative colitis who had already finished earlier trials. Researchers tracked side effects and checked if patients achieved remission over about 6.5 years. The goal was to see if the drug remains safe and effective for ongoing disease management.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLITIS, ULCERATIVE

Contacts and locations

Show contact details

Locations

AKH - Medical University of Vienna

Vienna, 1090, Austria
Asklepios Kliniken Westklinikum Hamburg

Hamburg, 22559, Germany
Azienda Ospedaliera Universitaria di Padova

Padova, 35128, Italy
Centre Hospitalier Universitaire de Liège

Liège, 4000, Belgium
Columbia University Medical Center-New York Presbyterian Hospital

New York, New York, 10032, United States
Digestive Disease Specialists Inc

Oklahoma City, Oklahoma, 73112, United States
Doncaster Royal Infirmary

Doncaster, DN2 5LT, United Kingdom
Emory University

Atlanta, Georgia, 30322, United States
FSB Instit. HC Irkutsk Scient.Cent. Sibirian Branch of Russ. Acad. Scien.

Irkutsk, 664033, Russia
Federal State Budgetary Institution " State Scientific Center of Coloproctology" MOH Russia

Moscow, 123423, Russia
Guy's Hospital

London, SE1 9RT, United Kingdom
Hospital Politècnic La Fe

Valencia, 46026, Spain
Hospital Virgen del Rocío

Seville, 41013, Spain
Hunter Holmes McGuire VA Medical Center

Richmond, Virginia, 23249, United States
Hyogo College of Medicine Hospital

Hyogo, Nishinomiya, 663-8501, Japan
Inje University Haeundae Paik Hospital

Busan, 48108, South Korea
Istituto Clinico Humanitas

Rozzano (MI), 20089, Italy
Klinikum Esslingen GmbH

Esslingen am Neckar, 73730, Germany
Medical Research Center of Connecticut, LLC

Hamden, Connecticut, 06518, United States
Medizinische Hochschule Hannover

Hanover, 30625, Germany
Military Medical Academy n.a. C. M. Kirov, St. Petersburg

Saint Petersburg, 194044, Russia
National Medical Institute MSWiA

Warsaw, 02-507, Poland
Ofuna Chuo Hospital

Kanagawa, Kamakura, 247-0056, Japan
Ordensklinikum Linz GmbH - Barmherzige Schwestern

Linz, 4010, Austria
Sapporo Higashi Tokushukai Hospital

Hokkaido, Sapporo, 065-0033, Japan
Sapporo Tokushukai Hospital

Hokkaido, Sapporo, 004-0041, Japan
Southern Star Research Institute, LLC

San Antonio, Texas, 78229, United States
Texas Digestive Disease Consultants - Southlake

Southlake, Texas, 76092, United States
Tokyo Medical and Dental University Hospital

Tokyo, Bunkyo-ku, 113-8519, Japan
Tokyo Yamate Medical Center

Tokyo, Shinjuku, 169-0073, Japan
UZ Leuven

Leuven, 3000, Belgium
University of Chicago

Chicago, Illinois, 60637, United States
Universitätsklinikum Erlangen

Erlangen, 91054, Germany
Universitätsklinikum Schleswig-Holstein, Campus Kiel

Kiel, 24105, Germany
Universitätsklinikum Ulm

Ulm, 89081, Germany
Victoria Hospital (LHSC)

London, Ontario, N6A 5W9, Canada
Whiston Hospital

Prescot, L35 5DR, United Kingdom
Yeungnam University Medical Center

Daegu, 42415, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.